Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the ...

While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of ...

As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two ...

With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half ...

With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

Patients taking Novo Nordisk’s blockbuster GLP-1 drug appear to be more likely to harbor thoughts of suicide or self-harm, ...

Experts say Novo Nordisk and Eli Lilly’s GLP-1 drugs are unlikely to reach more countries in the near term, but Sanofi’s ...

As the pharma industry awaits Congressional action on the bill, gaping holes in the domestic drug manufacturing ecosystem ...

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the ...

The federal judge’s decision Tuesday said the Federal Trade Commission exceeded its statutory authority in implementing a ...

Eli Lilly released topline Phase III data on Tuesday showing that after more than three years of follow-up, pre-diabetic ...

The recent invalidation of an AAV gene therapy patent overlooks the complexity of innovation in biotechnology and could put a ...